Lumos Pharma (LUMO) Set to Announce Earnings on Tuesday

Lumos Pharma (NASDAQ:LUMOGet Rating) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, May 10th. Analysts expect the company to announce earnings of ($0.92) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Lumos Pharma (NASDAQ:LUMOGet Rating) last announced its quarterly earnings results on Thursday, March 10th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.24. The firm had revenue of $0.22 million during the quarter. On average, analysts expect Lumos Pharma to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Shares of LUMO stock opened at $8.52 on Tuesday. Lumos Pharma has a fifty-two week low of $6.15 and a fifty-two week high of $12.38. The firm has a fifty day moving average price of $9.18.

A number of institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. purchased a new stake in Lumos Pharma during the 4th quarter worth about $2,467,000. Millennium Management LLC purchased a new stake in Lumos Pharma during the 3rd quarter worth about $146,000. Citadel Advisors LLC purchased a new stake in Lumos Pharma during the 3rd quarter worth about $113,000. Geode Capital Management LLC increased its position in Lumos Pharma by 22.3% during the 3rd quarter. Geode Capital Management LLC now owns 28,356 shares of the company’s stock worth $269,000 after purchasing an additional 5,164 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in Lumos Pharma by 30.0% during the 2nd quarter. Wells Fargo & Company MN now owns 215,958 shares of the company’s stock worth $2,159,000 after purchasing an additional 49,873 shares in the last quarter. Hedge funds and other institutional investors own 38.35% of the company’s stock.

Separately, Zacks Investment Research cut Lumos Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 5th.

Lumos Pharma Company Profile (Get Rating)

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders.

Further Reading

Earnings History for Lumos Pharma (NASDAQ:LUMO)

Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.